Cost-effectiveness study of treatment in patients with chronic hepatitis C;Analyse cout-efficacite du traitement de l'hepatite chronique C

Gastroenterologie Clinique et Biologique

Volumn 20, Issue 11, 1996, Pages 958-967

  Joliot, Evelyne ^a   Vanlemmens, Claire ^a   Kerleau, Monique ^b   Le Gales, Catherine ^b   Woronoff Lemsi, Marie Christine ^a   Flori, Yves Antoine ^c   Seror, Valérie ^b   Hrusovsky, Stefan ^a   Monnet, Elisabeth ^a   Bresson Hadni, Solange ^a   Miguet, Jean Philippe ^a  

^a UNIVERSITY HOSPITAL OF BESANÇON   (France)

^b BICÊTRE HOSPITAL   (France)

^c UNIVERSITÉ DE BOURGOGNE   (France)

Author keywords

alpha interferon; cirrhosis; cost; cost effectiveness analysis; treatment; viral hepatitis C

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT;

ARTICLE; CHRONIC HEPATITIS; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEPRESSION; HEPATITIS; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; NEUROPATHY; NEUTROPENIA; THYROID DISEASE; ADOLESCENT; ADULT; AGED; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; HEPATITIS C; HOSPITALIZATION; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY; TIME;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; FEMALE; HEPATITIS C; HEPATITIS, CHRONIC; HOSPITALIZATION; HUMANS; INTERFERON-ALPHA; LIVER CIRRHOSIS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 0030331366     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Desenclos JC, Drucker J, et le Groupe de l'Action Concertée Hépatite C. Action concertée hépatite C: résultats et propositions. Saint-Maurice: Réseau National de Santé Publique, octobre 1995.
2. Alter MJ, Margolis HS, Krawczynski K, Judson FN, Mares A, Alexander J, et al. The natural history of community-acquired hepatitis C in the United States. N Engl J Med 1992;327:1899-905.
3. Benhamou JP, Beraud C, Bouvet E, Buisson Y, Canton P, Dhumeaux D, et al. Conférence de consensus: La conduite à tenir vis-à-vis des hépatites virales en pratique de ville. Rev Fr Gastroenterol 1993;288:169-76.
4. Drummond MF, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes, Oxford: Oxford University Press, 1986.
5. Knodell RG, Ishak KG, William CB, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431-5.
6. Alberti A, Chemello L, Bonetti P, Casarin C, Diodati G, Cavalletto L, et al. Treatment with interferon(s) of community-acquired chronic hepatitis and cirrhosis type C. J Hepatol 1993;17:S123-6.
7. Hosoda K, Yokosuka O, Kato N, Ito Y, Ohto M, Omata M, et al. Long-term effects of alpha-interferon for treatment of chronic hepatitis in terms of histological changes with aminotransferase normalization and hepatitis C virus RNA seroconversion. Gastroenterol Jpn 1993;28:S115-7.
8. Saracco G, Rosina F, Abate ML, Chiandussi L, Gallo V, Cerutti E, et al. Long-term follow-up of patients with chronic hepatitis C treated with different doses of interferon α-2b. Hepatology 1993;18:1300-5.
9. Dusheiko GM, Zuckerman AJ. Treatment of chronic viral hepatitis. J Antimicrobiol Chemother 1993;32:A107-20.
10. Stuart-Harris R, Lauchlan R, Day R. The clinical application of the interferons: a review. Med J Aust 1992;156:869-72.
11. e ed. Paris: Editions Vidai, 1995;757.
12. Kerleau M, Flori YA, Nalpas B, Lanoe JL, Berthelot P, Fardeau-Gautier M. Analyse coût-avantage d'une politique de prévention vaccinale de l'hépatite virale B. Rev Epidemiol Sante Publique 1995;43:48-60.
13. Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trépo C, et al. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N Engl J Med 1995;332:1457-62.
14. Bailly F, Laurent F, Trépo C. Histoire naturelle et traitement de l'hépatite virale C. Rev Fr Gastroenterol 1993;285:64-72.
15. Davis LD. Interferon treatment of chronic hepatitis C. Am J Med 1994;96:A41-6.
16. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC, Perillo RP, et al. Treatment of chronic hepatitis C with recombinant interferon alfa: a multicenter randomized, controlled trial. N Engl J Med 1989;321:1501-6.
17. Marcellin P, Boyer N, Giostra E, Degott C, Couroucé AM, Degos F, et al. Recombinant human α-interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France. Hepatology 1991;13:393-7.
18. Dumas F, Delvert D, Fonk M, Trouette H, Raymond JM, Saint-Martin E, et al. Suivi à moyen terme des patients atteints d'une hépatite virale C ayant eu une réponse complète après traitement par interféron α (INF) (résumé). Gastroenterol Clin Biol 1994;18:A 186.
19. Michel P, Merle V, Gourier C, Hochain P, Colin R, Czernichow P. Efficience comparée de trois stratégies de prise en charge de l'hépatite chronique C. Influence sur le risque de cirrhose à 8 ans. Gastroenterol Clin Biol 1996;20:47-54.
20. Bréchot C. Hepatitis C virus genetic variability: clinical implications. In: Groupe Français d'Etudes Moléculaires des Hépatites (GEMHEP), ed. Hepatitis C virus: new diagnostics tools. Paris : John Libbey, 1994;1-15.
21. Laurent-Puig P, Dussaix E, Lavai C, Stuyver L, Wilber JC, Babany G, et al. Le génotypage du VHC, la virémie à un mois permettent-ils de prévoir la réponse au traitement par l'interféron des malades ayant une hépatite chronique C ? (résumé). Gastroenterol Clin Biol 1994;18:A4
22. Di Bisceglie AM, Fong TL, Fried MW, Swain MG, Bergasa NV, Shindo M, et al. Ribavirine therapy for 6 months in patients with chronic hepatitis C (abstract). Gastroenterology 1991;100:A734.
23. Reichard O, Glaumann H, Fryden A, Norkrans G, Schvarcz R, Sönnerborg A, et al. Two-year biochemical, virological, and histological follow-up in patients with chronic hepatitis C responding in a sustained fashion to interferon alfa-2b treatment. Hepatology 1995;21:918-22.
24. Saleh MG, Tibbs CJ, Koskinas J, Pereira LM, Bomford AB, Portmann BC, et al. Hepatic and extrahepatic hepatitis C virus replication in relation to response to interferon therapy. Hepatology 1994;20:1399-404.
25. Davis GL, Lau JY. Choice of appropriate end points of response to interferon therapy in chronic hepatitis C virus infection. J Hepatol 1995;22:S110-4.
26. Camps J, Cordoba J, Esteban JI. Pathophysiology of chronic hepatitis C. In: Miguet JP, Dhumeaux D, eds. Progress in Hepatology 1993. Paris: John Libbey, 1993;63-8.
27. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, et al. Randomised trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995;109:156-65.
28. Mazzella G, Accogli E, Sottili S, Festi D, Orsini M, Salzetta A, et al. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol 1996;24:141-7.
29. Poynard T, Leroy V, Cohard M. Mathurin P, Opolon P, Zarski JP. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C. Effects of dose and duration (abstract). Hepatology 1995;22:113A.
30. Serfaty L, Chazouillères O, Pawlotsky JM, Andréani T, Pellet C, Poupon R. Interferon alfa therapy in patients with chronic hepatitis C and persistently normal aminotransferase activity. Gastroenterology 1996;110:291-5.
31. Pessione F, Martinot M, Duchatelle V, Njapoum C, Martins-Amado V, Degos F, et al. L'alcool augmente la virémie chez les porteurs chroniques du virus de l'hépatite C (résumé). Gastroenterol Clin Biol 1996;20:A159.